Category - Markets

Maxim Group has initiated coverage of Mast Therapeutics (NYSE:MSTX) with a “buy” rating and price target of $5. The stock closed at 42 cents on Wednesday. Mast’s vepoloxamer is in the pivotal Phase 3 EPIC study, with...

Rodman & Renshaw has initiated coverage of CorMedix (NYSE:CRMD) with a “buy” rating and price target of $6.50. The stock closed at $2.48 on Wednesday. CorMedix is developing a novel catheter lock solution (CLS)...

Wedbush Securities has raised its price target for “outperform-rated” Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to $17 from $15. The stock finished at $11.16 on Wednesday. “Novadaq is the leader in the rapidly growing...

Euro Pacific Canada has upgraded Sophiris Bio (NASDAQ:SPHS) to “buy” from “hold” and raised its price target to $6 from $1 after the company reported positive one-year efficacy data from a Phase 3 study of PRX-302 in...

Stifel has initiated coverage of Strongbridge Biopharma plc (NASDAQ:SBBP), formerly Cortendo plc, with a “buy” rating and a $21 target price. The stock closed at $7.49 on Monday. Strongbridge is an endocrinology-focused...

Roth Capital Partners has upgraded Cogentix Medical (NASDAQ:CGNT) to “buy” from “neutral” and raised its target price to $3 from $1.85. The stock closed at $1.52 on Wednesday. “Given our confidence for Cogentix to...

Third quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 27% to $6.6-million from $5.2-million a year ago. A net total of 228 TearLab systems were added in the third quarter. “We delivered a strong growth quarter...

William Blair has launched coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $30 price target. The stock closed at $14.38 on Friday. Aclaris’ lead program, A-101, is a topical solution being...

H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of CASI Pharmaceuticals (NASDAQ:CASI) with a “buy” rating and $3 price target. The stock closed at $1.21 on Wednesday. CASI is a clinical-stage company...

Maxim Group has initiated coverage of Rock Creek Pharmaceuticals (NASDAQ:RCPI) with a “buy” rating and 12-month price target of $4. The stock closed at 83 cents on Monday. Rock Creek’s lead product, anatabine citrate...